⌕
Abbott Laboratories · ABT · NYSE
Tenet 45 · Mixed
Compare
$107.45−0.99%At closeTenet 45 · Mixed
$107.45−1.07 (−0.99%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$107.450.00 (0.00%)
After hours: Nov 16, 2026, 6:03 PM ET

Abbott Laboratories (ABT) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● Zacks Investment ResearchNov 16, 2026 · 08:50 ET
Here's How Abbott's EP Business Is Shaping Up for the Rest of 2026

ABT's EP business gains momentum as Volt adoption accelerates and new device launches expand its portfolio despite LAA market weakness.…

● GuruFocusNov 16, 2026 · 07:32 ET
Is ABT Overvalued? DCF Says Worth $76

On November 16, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company that has seen a challenging year with its stock price reflecting a…

● Defense WorldNov 16, 2026 · 03:51 ETEARNINGS EXPECTED BY JAN 25
11,649 Abbott Laboratories $ABT Shares Bought by AlTi Global Inc.

AlTi Global Inc. increased its position in shares of Abbott Laboratories (NYSE: ABT) by 114.9% during a recent quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional i…

● Defense WorldNov 14, 2026 · 03:47 ETEARNINGS EXPECTED BY JAN 25
Abbott Laboratories $ABT Stock: Allworth Financial LP Increases Position

Allworth Financial LP raised its holdings in Abbott Laboratories (NYSE: ABT) by 5.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 269,783…

● Zacks Investment ResearchNov 13, 2026 · 12:16 ETEARNINGS EXPECTED BY JAN 25
Should You Buy, Hold or Sell Abbott Stock Post-Q3 Earnings?

ABT's strong Q3 results, broad-based segment growth and Nutrition spin-off plans support its outlook, despite softer 2026 sales guidance.…

● Defense WorldNov 12, 2026 · 04:19 ETEARNINGS EXPECTED BY JAN 25
CenterBook Partners LP Acquires New Shares in Abbott Laboratories $ABT

CenterBook Partners LP bought a new position in shares of Abbott Laboratories (NYSE: ABT) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional i…

● Zacks Investment ResearchNov 11, 2026 · 17:26 ET
Is Trending Stock Abbott Laboratories (ABT) a Buy Now?

Abbott (ABT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.…

● Zacks Investment ResearchNov 11, 2026 · 12:51 ETEARNINGS EXPECTED BY JAN 25
Can UltiSynq Lead Boost Abbott's Cardiac Rhythm Management Business?

ABT's UltiSynq lead combines conduction system pacing and defibrillation, with strong clinical trial results supporting its potential to expand the company's cardiac rhythm management portfolio.…

● Defense WorldNov 8, 2026 · 03:49 ETEARNINGS EXPECTED BY JAN 25
Abbott Laboratories $ABT Stock: Allen Investment Management LLC Reduces Stake

Allen Investment Management LLC cut its stake in shares of Abbott Laboratories (NYSE: ABT) by 45.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 8,000…

● Defense WorldNov 8, 2026 · 03:49 ETEARNINGS EXPECTED BY JAN 25
Ashton Thomas Private Wealth LLC Buys 5,216 Shares of Abbott Laboratories $ABT

Ashton Thomas Private Wealth LLC boosted its stake in shares of Abbott Laboratories (NYSE: ABT) by 8.2% during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). …

● Defense WorldNov 4, 2026 · 03:57 ETEARNINGS EXPECTED BY JAN 25
99,391 Shares of Abbott Laboratories $ABT Bought by Associated Banc Corp

Associated Banc Corp acquired a new stake in Abbott Laboratories (NYSE: ABT) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired…

● Defense WorldNov 3, 2026 · 03:55 ETEARNINGS EXPECTED BY JAN 25
Abbott Laboratories $ABT Stock: Heritage Investors Management Corp Trims Holdings

Heritage Investors Management Corp decreased its stake in Abbott Laboratories (NYSE: ABT) by 17.0% in a recent quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The insti…

● BenzingaNov 2, 2026 · 12:48 ETEARNINGS EXPECTED BY JAN 25
Abbott Touts Favorable Outcomes In Cardiovascular Device Trials

Abbott Laboratories (NYSE:ABT) reported positive clinical trial results for two investigational cardiovascular devices at the Transcatheter Cardiovascular Therapeutics conference in San Diego, demonstrating high procedur…

● PRNewsWireNov 2, 2026 · 09:00 ETEARNINGS EXPECTED BY JAN 25
Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closure and low incidence of stroke

Late-breaking one-year VERITAS study results were presented at the Transcatheter Cardiovascular Therapeutics conference and simultaneously published in JACC: Cardiovascular Interventions; data show the device achieved hi…

● PRNewsWireNov 1, 2026 · 15:45 ET
Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Intravascular Lithotripsy System

SonicForce is an investigational coronary intravascular lithotripsy (IVL) system that uses acoustic pressure waves, similar to those used to break up kidney stones, to crack calcium in coronary arteries and restore blood…

● PRNewsWireOct 29, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease

CROWN-MV trial will evaluate the safety and effectiveness of investigational Cephea mitral valve replacement device Abbott's Cephea is designed to provide a new, minimally invasive option for treating mitral valve diseas…

● PRNewsWireOct 26, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment

Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part p…

● PRNewsWireOct 23, 2026 · 09:15 ETCOMPANY'S OWN WORDS
Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in colorectal cancer

Beta-CORRECT study shows a 10.6-fold higher risk of recurrence, reinforcing the prognostic value of molecular residual disease (MRD) testing 1 Building on its leadership in colorectal cancer screening with the Cologuard …

● PRNewsWireOct 21, 2026 · 07:30 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance

Third-quarter reported sales growth of 14.5 percent; comparable sales growth of 7.0 percent Third-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.42 Expands portfolio with key new product approvals ABBOTT P…

● PRNewsWireOct 21, 2026 · 07:25 ETCOMPANY'S OWN WORDS
Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies The new Nutrition company will be a global leader in the rapidly growing healthy nutrition market, with a portfol…

● PRNewsWireOct 7, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop

New powder combines 30 grams of high‑quality protein to help build muscle tissue,† 5 grams of creatine monohydrate to support muscle recovery‡* and 3 grams of calcium HMB (beta-hydroxy-beta-methylbutyrate) to help preser…

● PRNewsWireOct 5, 2026 · 09:00 ETCOMPANY'S OWN WORDS
Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition

For the first time, U.S. CardioMEMS patients will be able to view pulmonary artery pressure (PAP) readings and receive personalized medication updates through the CardioGuide HF App Rising PAP can signal worsening heart …

● PRNewsWireSep 30, 2026 · 09:00 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY JAN 25
Abbott hosts conference call for third-quarter earnings

ABBOTT PARK, Ill., Sept. 30, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2026 financial results on Wednesday, Oct. 21, before the market opens.…

Expected by Jan 25. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just ABT · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.